GCL
STLN

Glazer Capital LLC’s Starling Oncology STLN Stock Holding History

Glazer Capital LLC’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-266,085
Closed -$2.65M – 863
2021
Q3 		$2.65M Sell
266,085
-7,102
-3% -$70.5K 0.05% 363
2021
Q2 		$2.72M Sell
273,187
-108,499
-28% -$1.09M 0.04% 392
2021
Q1 		$3.8M Buy
381,686
+18,004
+5% +$192K 0.05% 376
2020
Q4 		$3.93M Sell
363,682
-62,054
-15% -$639K 0.14% 167
2020
Q3 		$4.42M Buy
+425,736
New +$4.42M 0.22% 117

Other funds holding STLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
PGM
Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TM
Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Glazer Capital LLC's STLN Position: Q4 2021 in Review

Glazer Capital LLC sold out of Starling Oncology (STLN) in Q4 2021, closing a stake of 266,085 shares — an estimated $2.65M sold.

Glazer Capital LLC first reported a position in STLN in Q3 2020 and held it in 5 quarters. The position peaked at $4.42M in Q3 2020. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

  • Glazer Capital LLC reported no remaining Starling Oncology position as of Q4 2021 after selling out during the quarter.
  • Glazer Capital LLC sold 266,085 Starling Oncology shares in Q4 2021, an estimated $2.65M.
  • Glazer Capital LLC first reported a position in Starling Oncology in Q3 2020 and held it in 5 quarters.
  • Glazer Capital LLC's Starling Oncology position peaked at $4.42M in Q3 2020.
  • 21 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2021.

Based on Glazer Capital LLC's 13F filing for Q4 2021, filed 14 Feb 2022.